Skip to main content
Steven Schild, MD, Radiation Oncology, Scottsdale, AZ, Mayo Clinic Hospital

StevenESchildMD

Radiation Oncology Scottsdale, AZ

Professor of Radiation Oncology David F. and Margaret T. Grohne Professorship in Novel Therapeutics for Cancer Research 1, Mayo Clinic Arizona

Dr. Schild is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Schild's full profile

Already have an account?

Summary

  • Steven E. Schild, M.D. was a radiation oncologist at Mayo Clinic’s Arizona campus, specializing in tumors of the lung, skin, and prostate. Dr. Schild was a professor of radiation oncology at Mayo Clinic College of Medicine and Science. He received his medical degree at Creighton University School of Medicine, where he was the valedictorian of his class, and completed his residency at Mayo School of Graduate Education in 1989. Dr. Schild received the Mayo Clinic Investigator of the Year Award and has been awarded the Distinguished Service Award twice by the American Board of Radiology, in addition to other titles. U.S. News & World Report ranks Mayo Clinic Arizona the #1 hospital in Arizona.

Education & Training

  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Residency, Radiation Oncology, 1986 - 1989
  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Internship, Internal Medicine, 1985 - 1986
  • Creighton University School of Medicine
    Creighton University School of MedicineClass of 1985
  • Creighton University
    Creighton UniversityBachelor's, 1978 - 1981

Certifications & Licensure

  • AZ State Medical License
    AZ State Medical License 1993 - 2025
  • FL State Medical License
    FL State Medical License 1989 - 2024
  • MN State Medical License
    MN State Medical License 1986 - 2024
  • American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2010-2014
  • Top Doctors:Arizona State Castle Connolly, 2013
  • America's Top Doctors for Cancer Castle Connolly, 2009-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A Novel and Individualized Robust Optimization Method Using Normalized Dose Interval Volume Constraints (NDIVC) for Intensity‐Modulated Proton Radiotherapy  
    Terence T Sio, Steven E Schild, Wei Liu, Medical Physics
  • Nuclear expression of p65 (rela) in patients receiving post-operative radiotherapy for locally advanced squamous cell carcinoma of the head and neck  
    Rades D, Huttenlocher S, Seibold ND, Gebhard MP, Thorns C, Hasselbacher K, Wollenberg B, Schild SE, BMC Cancer, 1/6/2015
  • SU-E-T-349: Effective Dose-Volume-Histogram Prediction Method Using Euclidean Distance Volume Histogram for Volumetric Modulated Arc Therapy to Treat Prostate Cancer  
    Shin J, Liang J, Schild S, Wong W, Liu W, Med Phys, 1/1/2015
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Magnetic resonance imaging of small fiducial markers for proton beam therapy.
    Hu Y, James J, Panda A, Vargas C, Silva A, Liu W, Shen J, Ding X, Paden R, Hanson J, Wong W, Schild S, Bues M, Med Phys, 1/1/2015
  • Effective dose-volume-histogram prediction method using euclidean distance volume histogram for volumetric modulated arc therapy to treat prostate cancer.
    Shin J, Liang J, Schild S, Wong W, Liu W, Med Phys, 1/1/2015
  • Plan robustness study of volumetric-modulated arc therapy vs. intensity-modulated radiation therapy for head and neck cancer.
    Liu W, Patel S, Shen J, Harrington D, Stoker J, Ding X, Hu Y, Wong W, Halyard M, Schild S, Ezzell G, Bues M, Med Phys, 1/1/2015
  • Join now to see all

Lectures

  • A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell ... 
    Chicago, IL - 1/1/2013
  • Scoring system predicting overall survival (OS) in patients (Pts) with non-small cell lung cancer (NSCLC). 
    Chicago, IL - 1/1/2013
  • A randomized double-blind phase II study of the Seneca Valley virus (NTX-010) versus placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or respon... 
    Chicago, IL - 1/1/2013
  • Join now to see all

Other

  • A Tool to Predict the Probability of Intracerebral Recurrence or New Cerebral Metastases After Whole-Brain Irradiation in Patients with Head-and-Neck Cancer 
    Steven Schild, MD, Anticancer Research
    https://www.doximity.com/articles/375b8850-5449-4c06-9476-7f4d79afc02b
    UpToDate, Wolters Kluwer Health - 2012-03-28
  • Hyperfractionated or Accelerated Hyperfractionated Re-Irradiation with ≥42 Gy in Combination with Paclitaxel for Secondary/Recurrent Head-and-Neck Cancer 
    Steven Schild, MD, Anticancer Research
    https://www.doximity.com/articles/108dbb19-d80e-4793-bd48-cbe41516d879
    UpToDate, Wolters Kluwer Health - 2012-09-04
  • Validation of a Survival Score for Patients Receiving Radiosurgery or Fractionated Stereotactic Radiotherapy for 1 to 3 Brain Metastases 
    Steven Schild, MD, Anticancer Research
    https://www.doximity.com/articles/de5b3c76-e7e2-48f7-a00c-2aa84b758eaf
    UpToDate, Wolters Kluwer Health - 2012-10-04
  • Join now to see all

Authored Content

  • Validation of a Survival Score for Patients Receiving Radiosurgery or Fractionated Stereotactic Radiotherapy for 1 to 3 Brain MetastasesNovember 2017

Professional Memberships

Hospital Affiliations